Ben-Arzi Assaf, Ehrlich Rita, Neumann Ron
Department of Ophthalmology, Rabin Medical Center, 39 Jabotinski St., Petah Tikva 4941492, Israel.
Sackler School of Medicine, Tel Aviv University, P.O. Box 39040, Tel Aviv 6997801, Israel.
Pharmaceutics. 2022 Apr 21;14(5):904. doi: 10.3390/pharmaceutics14050904.
The future continuous growth of the global older population augments the burden of retinal diseases worldwide. Retinal characteristics isolating and protecting the sensitive neuro-retina from the rest of the ocular tissues challenge drug delivery and promote research and development toward new horizons. In this review, we wish to describe the unmet medical needs, discuss the novel modes of delivery, and disclose to the reader a spectrum of older-to-novel drug delivery technologies, innovations, and the frontier of pharmacodelivery to the retina. Treating the main retinal diseases in the everlasting war against blindness and its associated morbidity has been growing steadily over the last two decades. Implants, new angiogenesis inhibitor agents, micro- and nano-carriers, and the anchored port delivery system are becoming new tools in this war. The revolution and evolution of new delivery methods might be just a few steps ahead, yet its assimilation in our daily clinical work may take time, due to medical, economical, and regulatory elements that need to be met in order to allow successful development and market utilization of new technologies. Therefore, further work is warranted, as detailed in this Special Issue.
全球老年人口的持续增长加重了全球视网膜疾病的负担。视网膜的特性将敏感的神经视网膜与眼部其他组织隔离开并加以保护，这对药物递送构成挑战，并推动了向新领域的研发。在本综述中，我们希望描述未满足的医疗需求，讨论新型递送模式，并向读者揭示一系列从传统到新型的药物递送技术、创新以及视网膜药物递送的前沿领域。在过去二十年中，在与失明及其相关发病率的持久战中，治疗主要视网膜疾病的工作一直在稳步增长。植入物、新型血管生成抑制剂、微载体和纳米载体以及锚定端口递送系统正在成为这场战争中的新工具。新递送方法的革命和演进可能仅几步之遥，但由于医疗、经济和监管等因素需要满足，以便新技术能够成功开发和投入市场使用，其在我们日常临床工作中的应用可能需要时间。因此，正如本期特刊所详述的，有必要开展进一步的工作。
